Update on Myelodysplastic Syndromes Classification and Prognosis

Dita Gratzinger; Peter L Greenberg

doi:10.1016/j.path.2013.08.005

Update on Myelodysplastic Syndromes Classification and Prognosis

Surg Pathol Clin. 2013 Dec;6(4):693-728. doi: 10.1016/j.path.2013.08.005. Epub 2013 Oct 21.

Authors

Dita Gratzinger¹, Peter L Greenberg²

Affiliations

¹ Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, L235, Stanford, CA 94305, USA. Electronic address: ditag@stanford.edu.
² Hematology Division, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

PMID: 26839194
DOI: 10.1016/j.path.2013.08.005

Abstract

Myelodysplastic syndromes (MDS) are a collection of cytogenetically heterogeneous clonal bone marrow (BM) failure disorders derived from aberrant hematopoietic stem cells in the setting of an aberrant hematopoietic stem cell niche. Patients suffer from variably progressive and symptomatic bone marrow failure with a risk of leukemic transformation. Diagnosis of MDS has long been based on morphologic assessment and blast percentage as in the original French-American-British classification. The recently developed Revised International Prognostic Scoring System provides improved prognostication using more refined cytogenetic, marrow blast, and cytopenia parameters. With the advent of deep sequencing technologies, dozens of molecular abnormalities have been identified in MDS.

Keywords: Cytogenetics; Cytopenia; Dysplasia; Idiopathic cytopenia of uncertain significance (ICUS); Myelodysplastic syndromes (MDS).